Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Zenlabs Ethica Limited is a leading pharmaceutical contract marketing and trading company in India, known for its diverse range of branded drugs.
The company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada, and has a strong focus on quality and affordable drug distribution.
In 2023, Zenlabs Ethica ventured into Neurology and Cytrics, reflecting its diversification and expansion into new therapeutic areas.
It offers over 600 products across various therapeutic segments, showcasing its comprehensive market outreach and product variety.
As a WHO GMP certified company, it upholds high-quality standards in manufacturing and distribution.
Commercial Services & Supplies
Diversified Commercial Services
18 Cr
High Risk
-9.2
21.5
—
2.2
39.99
16.50
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Zenlabs Ethica Ltd (ZENLABS) is currently trading at 27.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zenlabs Ethica Limited is a leading pharmaceutical contract marketing and trading company in India, known for its diverse range of branded drugs. The company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada, and has a strong focus on quality and affordable drug distribution. In 2023, Zenlabs Ethica ventured into Neurology and Cytrics, reflecting its diversification and expansion into new therapeutic areas. It offers over 600 products across various therapeutic segments, showcasing its comprehensive market outreach and product variety. As a WHO GMP certified company, it upholds high-quality standards in manufacturing and distribution.
Over the past 52 weeks, Zenlabs Ethica Ltd has traded between a low of ₹16.50 and a high of ₹39.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zenlabs Ethica Ltd has a market capitalization of approximately 18.88. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zenlabs Ethica Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -9.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 18.88 Cr, Zenlabs Ethica Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zenlabs Ethica Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zenlabs Ethica Ltd is -9.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
3
Neutral
2
Bullish
9
Bearish
31
Neutral
2
Bullish
13
Bearish
28
Neutral
0
Bullish
4
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
40.50 | 21 Cr | 86.25 | 4.03 | 0.00 | 4.53 | 5.77 | 3.92 | ||
28.25 | 20 Cr | 153.15 | 1.03 | 0.00 | 0.68 | 1.84 | 0.50 | ||
26.90 | 20 Cr | -984.00 | 0.84 | 0.00 | -0.12 | -0.17 | -0.09 | ||
31.50 | 20 Cr | 11.02 | 0.68 | 0.00 | 6.15 | 7.57 | 3.90 | ||
29.00 | 19 Cr | -9.73 | 2.22 | 0.00 | 0.23 | 5.22 | -5.21 | ||
0.48 | 18 Cr | 12.90 | 0.31 | 0.00 | 2.38 | 4.05 | 0.98 | ||
0.30 | 17 Cr | -40.86 | 0.30 | 0.00 | -0.71 | 0.55 | -0.61 | ||
| Median: 7 Co. | — | 28.25 | 20 Cr | 11.02 | 0.84 | 0.00 | 0.68 | 4.05 | 0.50 |
Change in Directors/KMP
Zenlabs Ethica Ltd informed that the Board appointed Mr. Sanjay Dhir as Chief Financial Officer. Board meeting held on 2026-07-21 from 11:00 to 11:30. Announcement under Reg 30; Annexure also notes effective date 2026-07-27.
Change in Directors/KMP
Zenlabs Ethica Ltd appointed Mr. Sanjay Dhir as Chief Financial Officer. Board meeting on 21 July 2026 commenced at 11:00 and concluded at 11:30. Annexure notes appointment effective from 27 July 2026.
